PharmaCyte Biotech Shares Surge 72% on 74% Q/C Technologies Stake Acquisition

Introduction

PharmaCyte Biotech Inc. (NASDAQ: PMCB) is a clinical stage biotechnology company headquartered in Las Vegas, Nevada. Founded in 1996, the company is developing cellular therapies for cancer and diabetes based on its proprietary cellulose-based live cell encapsulation platform, Cell-in-a-Box®.

Corporate Structure

PharmaCyte Biotech employs between two and ten staff members and maintains its primary office at 3960 Howard Hughes Parkway, Suite 500, Las Vegas, Nevada 89169. As a publicly traded company on the NASDAQ under the ticker PMCB, its organizational focus includes research, development, and corporate governance.

Biotechnology by Louis Reed

Developments and News

On November 7, 2025, an amendment to a Schedule 13G/A filing disclosed that Mitchell P. Kopin and Daniel B. Asher each beneficially own 9.99 percent of the company’s outstanding common stock. On November 18, 2025, PharmaCyte Biotech filed a Schedule 13D/A revealing the acquisition of 8,475,368 shares—representing 74.00 percent of Q/C Technologies, Inc.—in exchange for $3 million obtained through the conversion of preferred stock and exercise of warrants. A concurrent Form 8-K/A amendment addressed prior disclosures without providing detailed financial revisions. Trading on November 25, 2025, saw PMCB shares close at $1.12, reflecting a 72.31 percent increase on a volume of 16,514,725 shares.

Financial and Strategic Analysis

The share price of $1.12 on November 25, 2025, indicated a 72.31 percent intraday increase amid substantial trading volume. The acquisition of a majority stake in Q/C Technologies may enhance PharmaCyte’s technological capabilities. Significant ownership by key investors—each holding just under 10 percent as of November 7, 2025—suggests a concentrated shareholder base. Q/C Technologies conducted a 1-for-100 reverse stock split effective August 29, 2025, which will influence per-share valuation metrics going forward.

Market Position and Industry Context

Within the biotechnology research sector, PharmaCyte’s Cell-in-a-Box® technology supports treatment candidates for pancreatic cancer, Type 1 diabetes, and insulin-dependent Type 2 diabetes. The company is also exploring cannabinoid-based prodrug activation for challenging cancers such as glioblastoma. Operating as a small-cap public entity, PharmaCyte operates in an environment characterized by stringent regulatory requirements and significant funding needs for clinical development.

TL;DR

PharmaCyte Biotech’s stock rose 72.31 percent to $1.12 on November 25, 2025, following SEC filings detailing a 74.00 percent stake acquisition in Q/C Technologies and major shareholdings by key investors. The company continues to advance clinical data readouts for its Cell-in-a-Box® therapies and prepare regulatory submissions for cancer and diabetes programs.